Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. (Q34193749)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

title

Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author

Matthias A. Karajannis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Jeffrey H. Wisoff

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Judith D. Goldberg

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

David T. W. Jones

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Stefan M. Pfister

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Jeffrey Allen

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

13

Adam C Resnick

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

16

Andrey Korshunov

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

18

Charles G Eberhart

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

19

David Zagzag

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

5

Kenneth J Cohen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

14

Girish Dhall

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

Geneviève Legault

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Michael J Fisher

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Sarah S Milla

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

David H Harter

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Tsivia Hochman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Amanda Merkelson

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Michael C Bloom

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Angela J Sievert

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

publication date

6 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

1408-1416

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

17 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Gliomas in patients with neurofibromatosis type 1.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Pediatric low-grade gliomas and the need for new options for therapy: Why and how?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Dermatologic symptoms associated with the multikinase inhibitor sorafenib

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Molecular pathogenesis of pediatric astrocytic tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Optimal two-stage designs for phase II clinical trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

5 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU059

Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU059

Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU059

Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU059

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU059

Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU059

Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4165419

28 October 2018

Identifiers

DOI

10.1093/NEUONC/NOU059

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803676%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference